February 06, 2026

World Cancer Day: Taking a Proactive Approach to the Most Commonly Diagnosed Cancer

On World Cancer Day, marked annually on February 4, it’s important to note that skin cancer is the most frequently diagnosed cancer. One in every five Americans will experience some form of skin cancer by age 70, experts say.

Baptist Health South Florida

January 21, 2026

Bridging Structure and Biology in Eyelid Reconstruction

Optimizing the surgical approach to eyelid defect reconstruction using cryopreserved umbilical cord amniotic membrane (UC-AM)

The Ophthalmologist

January 21, 2026

The Topical Drug Delivery Challenge

From skin penetration to stability and spreadability; here’s what to consider if you want to develop a topical therapeutic

The Medicine Maker

January 16, 2026

Meet the Team: Eleanor Fallon, MD

Eleanor Fallon, MD, joined Roswell Park Comprehensive Cancer Center to combine her two passions: treating melanoma and non-melanoma skin cancers and research into how immunotherapy can be used to make other therapies more effective.

Roswell Park Comprehensive Cancer Center

January 09, 2026

Flipped Nivolumab/Ipilimumab Dosing Improves Responses, Survival, and Safety in Advanced Melanoma

The flipped dose for nivolumab 3 mg/kg and ipilimumab 1 mg/kg led to improved response rates and survival findings as well as lower severe immune-related toxicities compared with the standard dose of ...

The ASCO Post

October 29, 2025

Cutaneous Squamous Cell Carcinoma: AI Model Rivals Dermatologists in Differentiation Assessment

Performance of a convolutional neural network in determining differentiation levels of cutaneous squamous cell carcinomas was on par with that of experienced dermatologists, according to the results o...

The ASCO Post

October 06, 2025

Can Nicotinamide Reduce the Risk of Skin Cancer Development?

A retrospective study aimed to determine the clinical efficacy of nicotinamide supplementation for skin cancer prevention in the general population and among solid organ transplant recipients.

The ASCO Post

October 02, 2025

RP1 Oncolytic Therapy Provides New Hope for Patients Whose Melanoma Resists Conventional Immunotherapy

About half of all patients with advanced melanoma face a poor prognosis because their cancer doesn’t respond to immunotherapy — but results of a recent clinical trial show that an unusual treatment strategy could change that.

Roswell Park Comprehensive Cancer Center

September 17, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post